Quipt Home Medical Corp T.QIPT

Alternate Symbol(s): QIPT

Healthcare

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.

TSX:QIPT - Post by User

Quipt Home Medical Corp

Bullboard Posts

Post by NycePriceon Apr 01, 2015 2:09pm

197 Views

Post# 23587845

BIG Pharma Deal Looming

MOM looking for a POP

Anything Under a Dime "Should be Cleaned Up and Second Now"

BECAUSE this is Really OVERSOLD!

Miraculins’ focus is non-invasive medical diagnostic and risk assessment tests.

CHINA Deal that could eventually lead to as much as $90 million in revenue for Miraculins, Catalyn Medical Technologies Limited, a privately-owned and Hong Kong based medical device import company, has agreed to be the exclusive distributor in China of Miraculins’ Scout DS diabetes screening devices.

One of our major goals for 2015 will be to drive towards the goal of CFDA regulatory approval for the Scout DS® in China. This approval will trigger a $15M USD order of Scout DS® units and will be the first major revenue transaction for Miraculins.

image: https://stockcharts.com/c-sc/sc?s=MOM.V&p=D&yr=0&mn=5&dy=0&i=p50355111872&r=1427827575265

One of our major goals for 2015 will be to drive towards the goal of CFDA regulatory approval for the Scout DS® in China. This approval will trigger a $15M USD order of Scout DS® units and will be the first major revenue transaction for Miraculins. As part of this process, Miraculins is working hard to ensure that its manufacturing processes will be ready to effectively supply the market demand for the product both in China as well as other world markets.In addition, another major milestone for the Company will be achieving clarity from the U.S. FDA on the best path for regulatory approval for the Scout DS® and to begin the corresponding clinical trial. The Company is also planning to begin pilot programs for the Scout DS® both in the retail and food pharmacy market segment as well as the workplace screening segment in Canada

Read more at https://www.stockhouse.com/companies/bullboard/v.mom/miraculins-inc#DU4k2TGsqlTF255A.99

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity